Multi-center Study of Safety and Efficacy Evalution of Glimepiride in Type 2 Diabetic Patients

张俊清,郭晓蕙,洪旭,田慧,朱良香,肖文华,陈颖丽,王力,陈宇,安良,杜锦,袁申元,邓正照,卢纹凯,曹雪霞,高妍

DOI: https://doi.org/10.3969/j.issn.1001-6821.2003.06.002

2003-01-01

Abstract:Objective To assess the tolerance, safety and efficacy profile of glimepiride. Method One hundred twenty-nine type 2 diabetes patients who were treated with non-pharmacotherapy treatment or treated with metaformin and/or a -glucosidase inhibitor in a stable dosage more than one month were enrolled this multicenter non-comparative single group open assessment study. Patients received 16 weeks course of glimepiride 1~4 mg q.d according to the study plan. Results One hundred twenty-two patients fulfilled the trial. After 16 weeks glimepiride treatment, median fasting blood glucose (FBG), fasting plasma glucose (FPG), 2-hours postprandial blood glucose (2-hBG) were decreased 1.4,1.3 and 1.8 mmol.L-1, respectively. Glycosalated hemoglobin (GHbAIC) were decreased 1.8% (from 9.6% to 7.8%). Median body mass index (MBI) was increased 0.3 kg.m-2. There was no difference of fasting plasma insulin level between baseline and endpoint and had no adverse effects on blood pressure and blood lipid metabolism. The common treatment-related adverse events were hypoglycemic symptoms and digestive system disturbance. All hypoglycemic symptoms could be improved by taking foods themselves. Conclusion The results of this multicenter non-comparative single group open study indicated that glimepirid is a safe effective oral agent for lowing plasma glucose and GHbAIC in type 2 diabetic patients.